Andromeda Biotech Successfully Completes Patient Recruitment in Phase III Confirmatory Trial for Its Lead Drug, “DiaPep277" for Type 1 Diabetes

YAVNE, Israel, Sept. 12, 2012 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. (www.andromedabio.com) announced today that it has completed patient recruitment in its’ DIA-AID 2, a confirmatory Phase III clinical trial using DiaPep277® for the treatment of Type 1 diabetes.